Showing results (41-50 of 69) with videos related to

Sort By:
Pageof 7
Plos One|November 9, 2013
Identification and characterization of CDH1 germline variants in sporadic gastric cancer patients and in individuals at risk of gastric cancerMarica Garziera, Vincenzo Canzonieri, Renato Cannizzaro, et al.
American Journal of Clinical Pathology|April 24, 2012
Exocrine and endocrine modulation in common gastric carcinomaVincenzo Canzonieri, Cristina Colarossi, Laura Del Col, et al.
Oncotarget|September 1, 2016
p27kip1 expression limits H-Ras-driven transformation and tumorigenesis by both canonical and non-canonical mechanismsIlenia Pellizzari, Linda Fabris, Stefania Berton, et al.
Chemical Communications (Cambridge, England)|September 14, 2020
The anticancer activity of an air-stable Pd(I)-NHC (NHC = N-heterocyclic carbene) dimerThomas Scattolin, Enrica Bortolamiol, Stefano Palazzolo, et al.
Breast Cancer Research : BCR|November 25, 2011
A different immunologic profile characterizes patients with HER-2-overexpressing and HER-2-negative locally advanced breast cancer: implications for immune-based therapiesElena Muraro, Debora Martorelli, Elisa Turchet, et al.
Cell Death and Differentiation|February 8, 2019
Correction to: A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
Breast (Edinburgh, Scotland)|March 27, 2025
Long-term outcomes of three distinct once-daily schedules for accelerated partial breast irradiationLorenzo Vinante, Michele Avanzo, Angela Caroli, et al.
Cell Death and Differentiation|April 19, 2018
A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressivenessAlessandra di Gennaro, Valentina Damiano, Giulia Brisotto, et al.
Plos One|July 13, 2011
Antibody responses to NY-ESO-1 in primary breast cancer identify a subtype target for immunotherapyAhmed Hamaï, Karine Duperrier-Amouriaux, Pascale Pignon, et al.
BMC Cancer|December 17, 2014
Anthracycline-free neoadjuvant therapy induces pathological complete responses by exploiting immune proficiency in HER2+ breast cancer patientsGianmaria Miolo, Elena Muraro, Debora Martorelli, et al.
Pageof 7